Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. Stock Forecast & Price Prediction

Live Cerevel Therapeutics Holdings, Inc. Stock (CERE) Price
$41.06

9

Ratings

  • Buy 0
  • Hold 9
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$41.06

P/E Ratio

-17.69

Volume Traded Today

$1.7M

Dividend

Dividends not available for CERE

52 Week High/low

43.59/19.59

Cerevel Therapeutics Holdings, Inc. Market Cap

$7.43B

🛑 Alert: These ten stocks could have higher potential than $CERE 🛑

Before you buy CERE you’ll want to see this list of ten stocks that have huge potential. Want to see if CERE made the cut? Enter your email below

CERE Summary

Based on ratings from 9 stock analysts, the Cerevel Therapeutics Holdings, Inc. stock price is expected to increase by 3.65% in 12 months. This is calculated by using the average 12-month stock price forecast for Cerevel Therapeutics Holdings, Inc.. The lowest target is $25.00 and the highest is $45.00. Please note analyst price targets are not guaranteed and could be missed completely.

CERE Analyst Ratings

About 9 Wall Street analysts have assignedCERE 0 buy ratings, 9 hold ratings, and 0 sell ratings. This means that analysts expect Cerevel Therapeutics Holdings, Inc. to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CERE. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

CERE stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

jessica fye
J.P. Morgan

Hold

$45.0

maintained

Dec 28, 2023
mohit bansal
Wells Fargo

Hold

$45.0

maintained

Dec 22, 2023
michael yee
Jefferies

Hold

$45.0

downgraded

Dec 22, 2023
paul matteis
Stifel Nicolaus

Hold

$43.0

downgraded

Dec 18, 2023
douglas tsao
H.C. Wainwright

Hold

$45.0

downgraded

Dec 7, 2023
graig suvannavejh
Mizuho Securities

Hold

$25.0

maintained

Dec 7, 2023
joseph thome
TD Cowen

Hold

$45.0

downgraded

Dec 7, 2023
david amsellem
Piper Sandler

Hold

$45.0

downgraded

Dec 7, 2023
charles duncan
Cantor Fitzgerald

Hold

$45.0

rated

Dec 6, 2023
matthew harrison
Morgan Stanley

Buy

$38.0

maintained

Nov 2, 2023
tazeen ahmad
Bank of America Securities

Hold

$31.0

rated

Aug 3, 2023
caroline palomeque
Berenberg Bank

Hold

$24.0

maintained

Aug 3, 2023
madhu kumar
Goldman Sachs

Hold

$30.0

maintained

May 23, 2023
umer raffat
Evercore ISI

Buy

None

reiterated

Mar 20, 2023
esther hong
Loop Capital Markets

Buy

$38.0

maintained

Feb 23, 2023
cory kasimov
J.P. Morgan

Buy

$49.0

maintained

May 10, 2022
andrew tsai
Jefferies

Buy

$18.0

initiatedcoverage

Nov 23, 2020

CERE Company Information

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE
Cerevel Therapeutics Holdings, Inc. (CERE)

When did it IPO

2020

Staff Count

321

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Ronald C. Renaud Jr., M.B.A.

Market Cap

$7.43B

Cerevel Therapeutics Holdings, Inc. (CERE) Financial Data

In 2023, CERE generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CERE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -27.1%
  • Return on equity TTM -89.7%
  • Profit Margin 0.0%
  • Book Value Per Share 1.73%
  • Market capitalisation $7.43B
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $-2.50
... ...

Similar Stocks to Cerevel Therapeutics Holdings, Inc. - CERE

🛑 Alert: These ten stocks could have higher potential than $CERE 🛑

Before you buy CERE you’ll want to see this list of ten stocks that have huge potential. Want to see if CERE made the cut? Enter your email below

...

CERE Frequently asked questions

The highest forecasted price for CERE is $45.00 from charles duncan at Cantor Fitzgerald.

The lowest forecasted price for CERE is $25.00 from graig suvannavejh from Mizuho Securities

The CERE analyst ratings consensus are 0 buy ratings, 9 hold ratings, and 0 sell ratings.